The coronavirus pandemic has highlighted a major flaw in the delivery of healthcare in the United States. Extensive federal rules and regulations are preventing providers from offering high quality care to their patients in a timely manner.
The latest example of this issue was recently alleviated in the process of the development of new medical innovations. Despite being approved by an intensive Food and Drug Administration (FDA) process, a lag time still existed in between the approval and implementation periods for new innovative medical devices for Medicare participants. The Medicare Coverage of Innovative Technology (MCIT) rule, which is the final rule issued by the previous Administration’s Centers for Medicare and Medicaid Services (CMS), eliminated the lag time so that patients could have access to more advanced treatments right away.
You get the full article at The Economic Standard.